Catalytic organometallic anticancer complexes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Organometallic complexes offer chemistry that is not accessible to purely organic molecules and, hence, potentially new mechanisms of drug action. We show here that the presence of both an iodido ligand and a σ-donor/π-acceptor phenylazopyridine ligand confers remarkable inertness toward ligand substitution on the half-sandwich “piano-stool” ruthenium arene complexes [(η 6 -arene)Ru(azpy)I] + (where arene = p -cymene or biphenyl, and azpy = N , N -dimethylphenyl- or hydroxyphenyl-azopyridine) in aqueous solution. Surprisingly, despite this inertness, these complexes are highly cytotoxic to human ovarian A2780 and human lung A549 cancer cells. Fluorescence-trapping experiments in A549 cells suggest that the cytotoxicity arises from an increase in reactive oxygen species. Redox activity of these azopyridine Ru II complexes was confirmed by electrochemical measurements. The first one-electron reduction step (half-wave potential −0.2 to −0.4 V) is assignable to reduction of the azo group of the ligand. In contrast, the unbound azopyridine ligands are not readily reduced. Intriguingly the ruthenium complex acted as a catalyst in reactions with the tripeptide glutathione (γ- l -Glu- l -Cys-Gly), a strong reducing agent present in cells at millimolar concentrations; millimolar amounts of glutathione were oxidized to glutathione disulfide in the presence of micromolar ruthenium concentrations. A redox cycle involving glutathione attack on the azo bond of coordinated azopyridine is proposed. Such ligand-based redox reactions provide new concepts for the design of catalytic drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, many chemotherapeutics are known to increase the production of ROS in cancer cells.14, 15, 16”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [16]
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766 · cited 1×
“The concentration of the complexes that caused 50% inhibition of the growth (IC50) was determined by using the sulforhodamine-B (SRB) assay (39) as reported (13).”
MethodMeister, A., & Anderson, M. E. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.003431 · Cited by 5,680
Wang, H., & Joseph, J. A. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00107-0 · Cited by 2,346
Halliwell, B., & Whiteman, M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705776 · Cited by 2,238 · cited 2×
“This probe measures general oxidative stress (20).”
Hwang, T. L., & Shaka, A. J. (1995) · Journal of Magnetic Resonance, Series A · doi:10.1006/jmra.1995.1047 · Cited by 1,898
Fluorescence probes used for detection of reactive oxygen species
Gomes, A., Fernandes, E., & Lima, J. L. F. C. (2005) · Journal of Biochemical and Biophysical Methods · doi:10.1016/j.jbbm.2005.10.003 · Cited by 1,844 · cited 3×
“Excessive ROS generation inside cells is harmful, causing oxidation of biomolecules such as lipids, cell membranes, proteins, and DNA, and giving rise to oxidative stress (30).”
Aruoma, O. I., Halliwell, B., Hoey, B. M., & Butler, J. (1989) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(89)90066-x · Cited by 1,772 · cited 15×
“On the basis that GSH is the primary cellular antioxidant, it seems likely that the depletion of antioxidants is the primary mechanism by which ROS levels are increased and by which oxidative stress occurs in the systems studied here.”
InfluentialNew metal complexes as potential therapeutics
Zhang, C. X., & Lippard, S. J. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00081-4 · Cited by 946 · cited 1×
“Many examples are known of metal anticancer complexes containing metal–halide bonds that are activated in cells by hydrolysis and subsequently bind to DNA as a target, for example, PtII diam(m)ine complexes, including the drug cisplatin (21), and diamino RuII arene complexes (22).”
The role of glutathione in cancer
Balendiran, G. K., Dabur, R., & Fraser, D. (2004) · Cell Biochemistry and Function · doi:10.1002/cbf.1149 · Cited by 927
Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes
Morris, R. E., Aird, R. E., del Socorro Murdoch, P., Chen, H., Cummings, J., Hughes, N. D., Parsons, S., Parkin, A., Boyd, G., Jodrell, D. I., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010051m · Cited by 787
Self-citationAird, R. E., Cummings, J., Ritchie, A. A., Muir, M., Morris, R. E., Chen, H., Sadler, P. J., & Jodrell, D. I. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600290 · Cited by 582 · cited 3×
“7166 (7) Å for [( 6-indan)Ru(en)I] (12)}.”
Self-citationHabtemariam, A., Melchart, M., Fernández, R., Parsons, S., Oswald, I. D. H., Parkin, A., Fabbiani, F. P. A., Davidson, J. E., Dawson, A., Aird, R. E., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060596m · Cited by 456 · cited 2×
“The starting materials [( (6)-arene)RuCl2]2 (arene p-cymene, biphenyl) were prepared by reaction of RuCl3 xH2O with the reduced form of the arene (11), and the corresponding iodido dimers [( (6)-arene)RuI2]2 from the reaction of [( (6)-arene)RuCl2]2 with excess KI.”
Self-citationThe Chemistry of the Hydrazo, Azo and Azoxy Groups
(1975) · The Chemistry of Functional Groups · doi:10.1002/0470023414 · Cited by 424
Ohkuma, T., Utsumi, N., Tsutsumi, K., Murata, K., Sandoval, C., & Noyori, R. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0620989 · Cited by 374
Fish, R. H., & Jaouen, G. (2003) · Organometallics · doi:10.1021/om0300777 · Cited by 328
Moodie, F. M., Marwick, J. A., Anderson, C. S., Szulakowski, P., Biswas, S. K., Bauter, M. R., Kilty, I., & Rahman, I. (2004) · The FASEB Journal · doi:10.1096/fj.04-1506fje · Cited by 322
Wang, F., Habtemariam, A., van der Geer, E. P. L., Fernández, R., Melchart, M., Deeth, R. J., Aird, R., Guichard, S., Fabbiani, F. P. A., Lozano-Casal, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505798102 · Cited by 308 · cited 3×
“In this series of diamine complexes, changing the monodentate ligand X from chloride to iodide has little effect on activity; both are good leaving groups (12).”
Self-citationWang, F., Chen, H., Parsons, S., Oswald, I. D. H., Davidson, J. E., & Sadler, P. J. (2003) · Chemistry – A European Journal · doi:10.1002/chem.200304724 · Cited by 254 · cited 1×
“The Ru–Cl bond is labile, but hydrolysis is suppressed extracellularly because of the high chloride concentration, 104 mM (8).”
Self-citationAUDRIETH, L. F., & MOHR, P. H. (1948) · Chemical & Engineering News Archive · doi:10.1021/cen-v026n051.p3746 · Cited by 249
Correlation between Cytotoxicity and DNA Binding of Polypyridyl Ruthenium Complexes
Novakova, O., Kasparkova, J., Vrana, O., van Vliet, P. M., Reedijk, J., & Brabec, V. (1995) · Biochemistry · doi:10.1021/bi00038a034 · Cited by 246 · cited 1×
“DNA binding leads to further ‘‘downstream’’ effects, ultimately resulting in cell death (9, 10).”
The emerging role of reactive oxygen species in cancer therapy
Renschler, M. F. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.02.031 · Cited by 237 · cited 15×
“The TON was determined as follows: TON (cid:5) ( I GSSG /{ I GSH (cid:1) I GSSG })([GSH] 0 /[Ru]), where I GSSG / I GSH is the peak integral for oxidized/reduced glutathione, and [GSH] 0 is the initial concentration of GSH. ‘‘Quantofix’’ Peroxide Test Sticks (Aldrich; detection range 1–100 mg H 2 O 2 per liter) were us…”
InfluentialChou, W.-C., Jie, C., Kenedy, A. A., Jones, R. J., Trush, M. A., & Dang, C. V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306687101 · Cited by 234
Lo, H. C., Buriez, O., Kerr, J. B., & Fish, R. H. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19990517)38:10<1429::aid-anie1429>3.0.co;2-q · Cited by 230
Vessières, A., Top, S., Pigeon, P., Hillard, E., Boubeker, L., Spera, D., & Jaouen, G. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050251o · Cited by 206 · cited 1×
“For example, the redox activity of the organometallic ferrocenylphenol substitutents enhances the anticancer activity of tamoxifen derivatives by conferring an ability to generate reactive oxygen species in cells (3).”
Lest I Forget Thee, Glutathione …
KOSOWER, E. M., & KOSOWER, N. S. (1969) · Nature · doi:10.1038/224117a0 · Cited by 188 · cited 1×
“Such a process is reported to occur for the azo ester C6H5N NCOOCH3 (26) and for the diamide (CH3)2NCON NCON(CH3)2 (27).”
Goswami, S., Mukherjee, R., & Chakravorty, A. (1983) · Inorganic Chemistry · doi:10.1021/ic00162a012 · Cited by 187 · cited 1×
“Based on literature assignments for other ruthenium– phenylazopyridine complexes (14, 15), this reduction can be assigned to addition of an electron into the (cid”
Dougan, S. J., Melchart, M., Habtemariam, A., Parsons, S., & Sadler, P. J. (2006) · Inorganic Chemistry · doi:10.1021/ic061460h · Cited by 162 · cited 4×
“-acceptor-chelating ligand is incorporated into the complex, as we have discussed elsewhere (13).”
InfluentialSelf-citationBiomolecular Targets for Platinum Antitumor Drugs
Bose, R. N. (2002) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557024605500 · Cited by 101 · cited 1×
“GS-conjugation is the major deactivation mechanism for platinum complexes such as cisplatin (24).”
Hayward, R. L., Schornagel, Q. C., Tente, R., Macpherson, J. S., Aird, R. E., Guichard, S. M., Habtemariam, A., Sadler, P. J., & Jodrell, D. I. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0932-9 · Cited by 95 · cited 1×
“DNA binding leads to further ‘‘downstream’’ effects, ultimately resulting in cell death (9, 10).”
Self-citationDeAtley, S. M., Aksenov, M. Y., Aksenova, M. V., Harris, B., Hadley, R., Cole Harper, P., Carney, J. M., & Butterfield, D. A. (1999) · Cancer Letters · doi:10.1016/s0304-3835(98)00306-1 · Cited by 89 · cited 1×
“Several established anticancer drugs are known to generate ROS or other radicals, including adriamycin (33), arsenic trioxide (34), and cisplatin (35).”
Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications
Agostinelli, E., & Seiler, N. (2006) · Amino Acids · doi:10.1007/s00726-005-0271-8 · Cited by 85 · cited 1×
“Because cancer cells (mainly multidrug-resistant cells) are more sensitive to the additional exposure to ROS than normal cells (32), the proposal has been made that ROS can be used therapeutically to treat cancer (27, 31).”
Goswami, S., Chakravarty, A. R., & Chakravorty, A. (1983) · Inorganic Chemistry · doi:10.1021/ic00146a007 · Cited by 83 · cited 1×
“Based on literature assignments for other ruthenium– phenylazopyridine complexes (14, 15), this reduction can be assigned to addition of an electron into the * orbital centered on the azo group of the phenylazopyridine ligands to form the azo anion radical (–N N– e 3{–N–N–} ).”
Yan, Y. K., Melchart, M., Habtemariam, A., Peacock, A. F. A., & Sadler, P. J. (2006) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-006-0098-5 · Cited by 71
Self-citationSevere oxidatively damaged DNA after cisplatin treatment of cancer patients
Siomek, A., Tujakowski, J., Gackowski, D., Rozalski, R., Foksinski, M., Dziaman, T., Roszkowski, K., & Olinski, R. (2006) · International Journal of Cancer · doi:10.1002/ijc.22088 · Cited by 67 · cited 1×
“Several established anticancer drugs are known to generate ROS or other radicals, including adriamycin (33), arsenic trioxide (34), and cisplatin (35).”
Krause, R. A., & Krause, K. (1984) · Inorganic Chemistry · doi:10.1021/ic00182a042 · Cited by 53
Organometallic chemistry at the threshold of a new millennium. Retrospect and prospect
Halpern, J. (2001) · Pure and Applied Chemistry · doi:10.1351/pac200173020209 · Cited by 44
Glutathione. 6. Probable mechanism of action of diazene antibiotics
Kosower, E. M., & MIYADERA, T. (1972) · Journal of Medicinal Chemistry · doi:10.1021/jm00273a023 · Cited by 39 · cited 2×
“Because cancer cells (mainly multi-drug-resistant cells) are more sensitive to the additional exposure to ROS than normal cells (32), the proposal has been made that ROS can be used therapeutically to treat cancer (27, 31).”
Hansen, J. C. (1996) · Journal of Chemical Education · doi:10.1021/ed073p728 · Cited by 30 · cited 1×
“Such catalytic behavior of iodide toward H2O2 is well known (28) and explains the observed gas bubbles (O2).”
Santra, B. K., & Lahiri, G. K. (1997) · Journal of the Chemical Society Dalton Transactions · doi:10.1039/a700018i · Cited by 28
KRAUSE, R. A., & Krause, K. (1984) · ChemInform · doi:10.1002/chin.198441292 · Cited by 2 · cited 1×
“The relative order therefore reflects the decreasing -acceptor capability of the substituted azpy ligands with the addition of electrondonating groups onto the phenyl ring (16).”
Research works printed but not linked: 2
- PT Beurskens, et al. The DIRDIF-99 program system (Crystallography Laboratory, University of Nijmegen, The Netherlands, 1999).
- GM Sheldrick SHELXL-97 (University of Göttingen, Göttingen, Germany, 1997).
Cited by
Organometallic Anticancer Compounds
Gasser, G., Ott, I., & Metzler-Nolte, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm100020w · Cited by 1,624
“For example, Sheldrick et al. have used an automated multidimensional protein identification technology (MudPIT), which combined biphasic liquid chromatography with electrospray ionization tandem mass spectrometry (MS/MS) to analyze tryptic peptides from Escherichia coli cells, which were first treated with [(6-p-cyme…”
BackgroundReactive Oxygen Species in Cancer: Current Findings and Future Directions
Nakamura, H., & Takada, K. (2021) · Cancer Science · doi:10.1111/cas.15068 · Cited by 1,027
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z.-S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,017
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Self-citationAreneruthenium complexes as anticancer agents
Süß‐Fink, G. (2009) · Dalton Transactions · doi:10.1039/b916860p · Cited by 652
Metadata
- Authors
- Dougan, S. J., Habtemariam, A., McHale, S. E., Parsons, S., & Sadler, P. J.
- Affiliations
- University of Edinburgh (GB)
- University of Warwick (GB)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-08-19
- Volume
- 105
- Issue
- 33
- Pages
- 11628-11633
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2503924
- OpenAlex
- W2053726603
- Cited by
- 303
- References
- 40
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 12 · 2023: 16 · 2022: 13 · 2021: 21 · 2020: 25 · 2019: 25 · 2018: 22 · 2017: 17 · 2016: 28 · 2015: 18 · 2014: 15 · 2013: 17 · 2012: 18
- FWCI
- 6.88
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- University of Warwick
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Physical Sciences › Chemistry › Organic Chemistry › Organometallic Complex Synthesis and Catalysis
- Physical Sciences › Chemistry › Inorganic Chemistry › Inorganic and Organometallic Chemistry
- Keywords
- ruthenium(II) arene complexes, reactive oxygen species, glutathione oxidation, glutathione disulfide, azo bond reduction, redox cycling, cytotoxicity, A549 cells, A2780 cells
- MeSH terms
- Antineoplastic Agents, Catalysis, Cell Survival, Electrochemistry, Glutathione, Humans, Neoplasms, Organometallic Compounds, Oxidation-Reduction, Structure-Activity Relationship, Molecular Structure, Reactive Oxygen Species, Ruthenium Compounds, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.